Table 6.
Genomic aberrations among patients with stable disease ≥24 weeks and in the patient with 28% tumour shrinkage.
| Patient | Tumour type | Best response | Cycles | Prior lines | Prior PARPi | Relevant genomic alterations |
|---|---|---|---|---|---|---|
| 1 | Ovarian (HGSOC) | SD | 14 | 11 | NO | ARID1A, TP53 mutations |
| 2 | Uterine serous | SD | 8 | 3 | NO | KRAS, PIK3CA, TP53 mutations, RB1 mutation and copy loss |
| 3 | HGSOC | SD | 6 | 7 | Yes (x2) | gBRCA1, TP53 mutations |
| 4 | Malignant solitary fibrous tumour | SD | 8 | 2 | NO | PIK3CA mutation |
| 5 | HGSOC | SD | 6 | 4 | NO | TP53 mutation, CCNE1 gain |
| 6 | HGSOC | SD | 10 | 7 | Yes (x2) | BRCA2, TP53 mutations |
| 7 | Uterine high-grade endometrioid | SD | 8 | 3 | NO | TP53, CTNNB1, PTEN mutations |
| 8 | Ovarian carcinosarcoma | SD (−28%) | 3 | 7 | NO | TP53 mutation, CCNE1 amplification |